Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 32Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Neoplasm Metastasis 3Carcinoma, Ovarian Epithelial 3Pancreatic Neoplasms 2Lung Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Sarcoma 1Recurrent Uterine Corpus Sarcoma 1Recurrence 1Pain 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Liver Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Endometrial Adenocarcinoma 1

Interventions

Gemcitabine 153Fluorouracil 45Capecitabine 45130-nm albumin-bound paclitaxel 43Oxaliplatin 42Albumin-Bound Paclitaxel 39Leucovorin 31Erlotinib Hydrochloride 30pembrolizumab 23Radiotherapy 22Irinotecan 22Radiosurgery 20Bevacizumab 19Docetaxel 17Cyclophosphamide 17Taxes 13Cisplatin 13Cetuximab 13folfirinox 12Nivolumab 11Surgical Procedures, Operative 7Paclitaxel 7Ipilimumab 7dehydroftorafur 6Standard of Care 6Radiation 6Magnetic Resonance Spectroscopy 6spartalizumab 5ruxolitinib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Pancreatic Neoplasms × ixabepilone × Clear all
NCT01012362 2017-12-28

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
31 enrolled 12 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT00383149 2016-03-10

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

R-Pharm

Phase 2 Completed
58 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡